Oncolytics Biotech® Will Attend Fireplace Chat At RBC Capital Markets Global Health Conference 2022

Oncolytics Biotech® Will Attend Fireplace Chat At RBC Capital Markets Global Health Conference 2022

SAN DIEGO, California And CALGARY, AB, May 10, 2022 / CNW / – Oncolytic biotechnologies® Inc. (NASDAQ: ONCY) (TSX: ONC) announced today that Dr. Matt CoffeyPresident and CEO, will attend a chat in front of the fire at the RBC Capital Markets 2022 Global Health Conference, which is taking place May 17-18, 2022 at the InterContinental New York Barclay a New York, New York. More details on the fireplace chat can be found below.

Date: Wednesday 18 May 2022

Time: 11am ET

Position: InterContinental New York Barclay Morgan Suite, mezzanine floor

Webcast link: Available by clicking here

The company’s management will also participate in individual meetings with investors at the conference. To schedule a meeting, contact your RBC representative or send an email [email protected].

A live webcast of the Company’s presentation will also be available on the Investor Relations page of the Oncolytics website (LINK) and will be archived until August 15, 2022.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company that develops pelareorep, an intravenously administered immunotherapy agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype – turning “cold” tumors into “hot” tumors – through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has shown synergies with immune checkpoint inhibitors and may also be synergistic with other approved cancer treatments. Oncolytics is currently conducting and planning clinical trials to evaluate pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematologic malignancies as it progresses towards a registration study in metastatic breast cancer. For more information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, pursuant to Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding Oncolytics’ belief in the potential and benefits of pelareorep as a cancer therapy; our plans to move towards a registration study in metastatic breast cancer; and other statements regarding anticipated developments in Oncolytics’ business and technologies. In any forward-looking statement where Oncolytics expresses an expectation or belief about future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there is no guarantee that the statement or expectation or belief will be reached up. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, inter alia, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical trials and trials, the ability to Oncolytics to successfully commercialize pelareorep, uncertainties related to research and development of pharmaceutical products, uncertainties related to the regulatory process and general changes in the economic environment. In particular, we may be affected by business disruptions due to the COVID-19 coronavirus, including delays and disruptions in operations, production supply chain, clinical trials and project development, labor shortages, disruptions to travel and shipping and arrests (including due to government regulatory and preventive measures). It is not known whether and how oncolytics can be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events beyond our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics’ quarterly and annual documents at the Canadian and US securities committees for more information on the risks and uncertainties surrounding forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update these forward-looking statements, except as required by applicable law.

Company contact

Jon Patton

Director of IR and communication

+ 1-858-886-7813

[email protected]

Investor Relations for Oncolitics

Timothy McCarthy

LifeSci Consultants


[email protected]

SOURCE Oncolytics Biotech® Inc.


Leave a Comment

Your email address will not be published.